Patent Application
20180169208
The following application contains a sequence listing in computer readable format (CRF), submitted as a text file in ASCII format entitled “SequenceListing,” created on Jan. 4, 2016, as 25 KB. The content of the CRF is hereby incorporated by reference.
The present invention relates to stabilized protective antigen complexes and compositions, methods, and kits related to the same.
Protein subunit vaccines tend to be unstable and readily undergo physical and/or chemical degradation. There is a need for stabilized vaccines not only for storage during distribution, but for the preservation of native structures that are critical to inducing protective immunity.
The etiologic agent of anthrax (Bacillus anthracis) is a potential threat as an agent of biowarfare or bioterrorism because exposure to aerosolized B. anthracis spores can be lethal to mammals, such as humans. Anthrax toxin is a member of the class of bacterial toxins termed A-B toxins. A-B toxins are composed of two moieties. The A moiety is the enzymic portion of the toxin that catalyzes the toxic effect upon a cytoplasmic target within a target cell. The B moiety binds to a cellular receptor and facilitates the translocation of the A moiety across the cell membrane into the cytoplasm of the cell.
The B moieties of A-B toxins from tetanus, botulinum, diphtheria, and anthrax all form channels in membranes. The A and B moieties of anthrax toxin are secreted from the bacterial cell as distinct polypeptides. The A and B subunits of other A-B toxins are produced as single chain polypeptides or as separate chains that are assembled into oligomeric toxins before release from the bacteria.
The A-B toxin secreted from Bacillus anthracis is comprised of the B moiety protective antigen (“PA”), and the A moieties edema factor (“EF”), and lethal factor (“LF”). EF is a calmodulin-dependent adenylate cyclase which may protect the bacteria from destruction by phagocytes. LF is a metalloprotease that can kill macrophages or, at lower concentrations, prevent macrophages from secreting cytokines, resulting in a compromised host immunity. PA is a channel forming polypeptide that allows entry of EF and LF across membranes into the cell, a step that is critical for the pathogenesis of anthrax. PA is secreted as a four-domain, 83 kD protein that recognizes on the host cells the von-Willebrand factor A domain (“VWA”) of two integrin-like receptors: anthrax toxin receptor 1, (“ANTXR1”, formerly anthrax toxin receptor-tumor endothelial marker 8), and anthrax toxin receptor 2 (“ANTXR2”, formerly capillary morphogenesis protein 2 (“CMG2”)). Binding of PA to the receptor results in the proteolytic cleavage of PA by a furin-like protease on the cell surface, releasing the first 167 amino acid residues of domain 1. Thus, the C-terminal 63 kDa fragment (“PA63”) remains bound to the cell and the N-terminal 20 kDa fragment (“PA20”) dissociates from PA63. This proteolytic cleavage and subsequent dissociation of PA20 confer at least two new properties on PA63: (1) the ability to oligomerize into a ring-shaped heptameric sodium dodecyl sulfate (“SDS”)-dissociable structure termed prepore and (2) the ability to bind EF and LF, which bind with a stoichiometry of three per heptameric prepore. Binding of PA to the receptor also initiates receptor-mediated endocytosis into an endosomal compartment, which eventually becomes acidified. The low pH within the endosome induces a conformational change in the protective antigen that results in the formation of a membrane spanning channel, and this new conformation of the entire PA heptamer is termed the pore. The pore allows the transport of EF and LF into the cytosol. The exact pH required for pore formation is dependent upon interactions with the receptor—in vitro studies indicate that the pH is about 5 if the receptor is ANTXR2, and a slightly higher pH (about 6) if the receptor is ANTXR1. The receptor then dissociates from PA, allowing conformational changes to occur throughout the protein such that PA forms a membrane spanning pore. Modified forms of PA have been developed for use as vaccine and antitoxins, including those described in U.S. Pat. No. 7,731,979, incorporated by reference herein in its entirety. However, storage and stability of such proteins remains a significant challenge.
The present invention is broadly concerned with immunogenic compositions against Bacillus anthracis infection comprising a stabilized protective antigen complex. The stabilized complex comprises protective antigen protein and capillary morphogenesis protein-2. The capillary morphogenesis protein-2 is bound to protective antigen protein along a binding interface which increases the thermal and/or structural stability of the protective antigen, and imparts resistance to degradation.
Methods for inducing an immunogenic response in a subject against B. anthracis are also disclosed. The methods generally comprising administering to the subject a therapeutically-effective amount of an immunogenic composition according to the various embodiments of the invention.
Kits for vaccinating a subject against B. anthracis infection are also disclosed. The kits generally comprise a unit dosage form of an immunogenic composition according to the various embodiments of the invention and instructions for administering the unit dosage form to the subject.
Also described herein are methods for stabilizing protective antigen for a vaccine or antitoxin against B. anthracis. The methods generally comprise providing an immunogenic composition against B. anthracis infection, which comprises protective antigen, and adding purified capillary morphogenesis protein-2 to the composition. Advantageously, the resulting composition has increased thermal stability, and does not require a cold chain for storage and transportation.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
In more detail, described herein are methods of stabilizing PA, pharmaceutical compositions comprising stabilized PA complexes, vaccines, antitoxins, and therapeutic and prophylactic uses thereof. In particular, the invention is directed towards PA formulations with improved stability that do not require use of a cold chain for storage.
In one or more embodiments, described herein are stabilized PA complexes comprising (consisting essentially or even consisting of) PA and capillary morphogenesis protein-2 (CMG2). In one or more embodiments, CMG2 and PA interact along a binding interface, with direct interaction with CMG2 at His616 in domain 4, and indirect interaction at His211 and His253 in domain 1′, such that a stabilized conformation of the PA protein is achieved in the PA-CMG2 complex. In one or more embodiments, the stabilized PA complex comprises an altered pKa of His86 in the PA20 domain of PA in the complex. In one more embodiments, PA in the complex is modified such that the PA has decreased flexibility in the domain 2-domain 4 interface as compared to an uncomplexed PA protein. Thus, references herein to PA being “stable” or “stabilized” mean that the PA in the inventive complex has been made resistant to change from its “initial form” (defined as the original phenotype of the same PA before complexation). Thus, in the invention the PA in the complex is stabilized thermodynamically and/or physically/structurally, and/or is resistant to proteolysis and/or premature degradation of the protein in vivo after administration.
Wild type PA can be used in the complex, as well as PA having fluorinated histidine residues (such as those described in U.S. Pat. No. 7,731,979, incorporated by reference herein in its entirety), and mutated forms of PA having affinity for CMG2. In one or more embodiments, at least isolated PA20 (residues 1-167) domain is used in the complex. In one or more embodiments PA83 is used in the complex. In one or more embodiments, the protective antigen for use in the complex is isolated from the other B. anthracis exotoxins. In some embodiments, the stabilized protective antigen complex itself is preferably free of edema factor (EF) and/or lethal factor (LF). That is, the immunogenic component in the stabilized complex against B. anthracis preferably consists of the (isolated) protective antigen protein, although it will be appreciated that EF and/or LF may be included in the compositions separate from the stabilized complex itself. In one or more embodiments, the PA is a polypeptide that is at least 80%, preferably at least 90%, more preferably at least 95%, still more preferably at least 97%, or most preferably at least 99% identical to GenBank AF306778 (SEQ ID NO. 1), which is incorporated by reference. In one or more embodiments, the polypeptide is encoded by SEQ ID NO:2, or a sequence having at least 80%, preferably at least 90%, more preferably at least 95%, still more preferably at least 97%, or most preferably at least 99% identical to SEQ ID NO:2. The polypeptide may be encoded by the PA gene that was reported by Vodkin et al., Cloning of the protective antigen gene of Bacillus anthracis, Cell 34 693-697 (1983). The polypeptide can be at least 97%, most preferably at least 99%, and most preferably identical to wild-type PA characterized by Miller et al., Anthrax Protective Antigen. Prepore-to Pore Conversion, Biochemistry 38β2) 10432-10441 (1999), UniProt:Swiss-Prot: P13423 (SEQ ID NO:3), which is incorporated by reference, or any naturally-occurring (wild type) PA polypeptide from a strain of Bacillus anthracis. The PA polypeptide may be cloned and expressed in a heterologous host such as Escherichia coli or Bacillus subtilis. It is understood that homologs and analogs have the characteristics of the anthrax PA described herein and may be used in the methods of the invention. The term also includes any recombinant B. anthracis PA, or other modified form (variant).
The CMG2 for use in the invention preferably comprises, consists essentially, or even consists of purified forms of CMG2, and in particular, artificially (in vitro) expressed and/or synthetically created forms of CMG2 that have been purified for use in the complex. In other words, the CMG2 for use in the complex is not a naturally occurring or naturally-derived CMG2 from an in vivo source. In one or more embodiments, the CMG2 for use in the invention comprises (consists essentially or even consists of) SEQ ID NO:4. In one or more embodiments, CMG2 for use in the invention comprises at least the von Willebrand factor A (vWA) domain (residues 38-218) of CMG2 (Uniprot: P58335, Isoform 1, incorporated by reference herein; SEQ ID NO:4). In one or more embodiments, the CMG2 for use in the invention comprises (consists essentially or even consists of) residues 225-406 of SEQ ID NO:5. In one or more embodiments, CMG2 for use in the invention consists essentially of the vWA domain or even consists of the vWA domain of CMG2 (i.e., in lieu of the full length protein), or functional fragments thereof. In one or more embodiments, the CMG2 may be labeled (e.g., with a fluorinated residue).
The PA-CMG2 complexes are useful as both a vaccine and an antitoxin, providing epitopes for the production of antibodies against PA, but preventing key steps in pathogenesis (pore formation, translocation). The PA-CMG2 complexes in the invention have increased thermal stability, and in particular may have improved thermal stability that is about 20° C. higher than the thermal stability of uncomplexed PA. The PA-CMG2 complexes also have reduced rates of proteolysis by thermolysin. The CMG2 also reduces premature degradation of the PA protein, allowing a higher proportion of PA to be present for interacting with the host immune system.
Pharmaceutical compositions comprising the PA-CMG2 complex are also contemplated herein. Those skilled in the art will appreciate that depending on the intended mode of administration, the PA-CMG2 complex can be in various pharmaceutical compositions. The compositions will comprise the PA-CMG2 complex in a therapeutically effective amount in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants (immunopotentiating agents), diluents, etc. As used herein, the term “pharmaceutically acceptable” means not biologically or otherwise undesirable, in that it can be administered to a subject without excessive toxicity, irritation, or allergic response, and does not cause unacceptable biological effects or interact in a deleterious manner with any of the other components of the composition in which it is contained. A pharmaceutically-acceptable carrier would naturally be selected to minimize any degradation of the compound or other agents and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
The immunogenic compositions of the present invention may be formulated by dispersing the PA-CMG2 complex in the desired amount in any pharmaceutical carrier suitable for use in vaccines. Any pharmaceutical carrier suitable for administration to mammals which does not interfere with the immunogenicity of the modified PA protein may be employed. Exemplary carriers include aqueous solutions such as normal (n.) saline (˜0.9% NaCl), phosphate buffered saline (PBS), sterile water/distilled autoclaved water (DAW), various oil-in-water or water-in-oil emulsions, as well as dimethyl sulfoxide (DMSO) or other acceptable vehicles, and the like. The compositions can further include an antibody against lethal factor and/or an antibody against edema factor of B. anthracis dispersed in the carrier.
Methods for therapeutic and prophylactic use of the PA-CMG2 complexes are also contemplated herein. In one aspect, a method for inducing an immunogenic response in a subject is described, which comprises administering to the subject a therapeutically-effective amount of the PA-CMG2 complex. As used herein, a “therapeutically-effective” amount refers to the amount that will elicit the biological or medical response of a tissue, system, or subject that is being sought by a researcher or clinician, and in particular elicit some desired therapeutic or prophylactic effect as against the anthrax infection by preventing and/or inhibiting toxin activity and/or pathogenesis of the toxin (e.g., through infiltration across the cell membrane in the subject). One of skill in the art recognizes that an amount may be considered therapeutically “effective” even if the condition is not totally eradicated or prevented, but it or its symptoms and/or effects are improved or alleviated partially in the subject.
Methods for inhibiting translocation of lethal factor or edema factor in a mammalian cell are also described, which comprise administering to the subject a therapeutically-effective amount of the PA-CMG2 complex. Methods for blocking pore formation in a cell expressing anthrax toxin receptor 2 are also described, which comprise administering to the subject a therapeutically-effective amount of the PA-CMG2 complex.
Compositions according to the embodiments disclosed herein are useful in treating and/or preventing anthrax infection by eliciting an immune response against B. anthracis in a subject. Thus, embodiments described herein have broad-spectrum therapeutic and/or prophylactic uses. The terms “therapeutic” or “treat,” as used herein, refer to processes that are intended to produce a beneficial change in an existing condition (e.g., infection, disease, disorder) of a subject, such as by reducing the severity of the clinical symptoms and/or effects of the infection, and/or reducing the duration of the infection/symptoms/effects in the subject (who has already been infected). The terms “prophylactic” or “prevent,” as used herein, refer to processes that are intended to inhibit or ameliorate the effects of a future infection or disease to which a subject may be exposed (but is not known to be currently infected with). In some embodiments, the vaccine is used as a postexposure prophylaxis countermeasure. In some cases the composition may prevent the development of observable morbidity from infection (i.e., near 100% prevention). In other cases, the composition may only partially prevent and/or lessen the extent of morbidity due to the infection (i.e., reduce the severity of the symptoms and/or effects of the infection, and/or reduce the duration of the infection/symptoms/effects). In either case, the compounds are still considered to “prevent” the target infection or disease, in the context of the present application.
In one or more embodiments, immunogenic compositions according to the invention can be used to induce protective immunity in the subject. The term “immunogenic” refers to the ability of the composition or its constituents to provoke an immune response in the subject after administration. The terms “protection” or “protective immunity” refers herein to the ability of the serum antibodies and cellular response induced during immunization to protect (partially or totally) against B. anthracis infection. Thus, a subject immunized by the pharmaceutical compositions or vaccines of the invention will experience limited growth and spread of the B. anthracis organism compared to an unvaccinated control.
In some embodiments, the subject is afflicted with or suffering from a condition (e.g., infection, disease, or disorder) before the compounds are administered, wherein methods described herein are useful for treating the condition and/or ameliorating the effects of the condition. A subject suffering from Bacillus anthracis infection may be identified by methods known in the art, e.g., by isolating B. anthracis from a biological sample (e.g., blood, respiratory secretions, etc.) from the subject. Symptoms of B. anthracis infection include fever (temperature greater than 100° F.), chills or night sweats, flu-like symptoms, cough, usually a non-productive cough, chest discomfort, shortness of breath, fatigue, muscle aches, sore throat, followed by difficulty swallowing, enlarged lymph nodes, headache, nausea, loss of appetite, abdominal distress, vomiting, or diarrhea or in the case of cutaneous contraction, a sore, especially on the face, arms or hands, that starts as a raised bump and develops into a painless ulcer with a black area in the center.
In other embodiments, the subject is free of observable signs of Bacillus anthracis infection before administering the composition, wherein the methods described herein are useful for preventing the occurrence or incidence of the condition and/or preventing the effects of the condition, as described above. In some embodiments, the subject is at risk of developing
Bacillus anthracis infection. A subject suffering at risk of developing Bacillus anthracis infection may be identified by methods known in the art, e.g., by isolating B. anthracis from the blood, skin lesions, or respiratory secretions or by measuring specific antibodies in the blood.
The invention also relates to methods of using the PA-CMG2 complex(es), and/or compositions thereof, to induce serum antibodies against PA. The PA-CMG2 complex(es), and/or compositions thereof, are useful as vaccines to induce serum antibodies which are useful to prevent, treat, or reduce the severity of infections caused by B. anthracis, such as inhalation anthrax and/or cutaneous anthrax. The PA-CMG2 complex(es) of this invention are expected to induce a strong protective IgG antibody response in mammals, including humans.
The disclosed embodiments are suitable for various routes of administration, depending upon the particular carrier and other ingredients used. For example, the prophylactic and/or therapeutic compounds or compositions can be injected intramuscularly, subcutaneously, intradermally, or intravenously. They can also be administered via mucosa such as intranasally or orally.
In some embodiments, the compound or compositions can be provided in unit dosage form in a suitable container. The term “unit dosage form” refers to a physically discrete unit suitable as a unitary dosage for human or animal use. Each unit dosage form may contain a predetermined amount of the inventive compound (and/or other active agents) in the carrier calculated to produce a desired effect. The invention also relates to kits for vaccinating mammals for the treatment or prevention of B. anthracis infection in a mammal comprising the PA-CMG2 complex(es) of the invention.
The PA-CMG2 complex(es) of the invention can be co-administered with one or more other therapeutic or immunostimulatory agents. Further, the PA-CMG2 complex(es) can be administered before, after or concurrently with the agent or can be co-administered with other known therapies including anthrax vaccines, antibodies against LF, EF, PA, and B. anthracis antibiotics, e.g., amoxicillin, penicillin G procaine, ciprofloxacin, doxycycline, chloramphenicol, clindamycin, tetracycline, rifampin, and vancomycin.
Additional advantages of the various embodiments of the invention will be apparent to those skilled in the art upon review of the disclosure herein and the working examples below. It will be appreciated that the various embodiments described herein are not necessarily mutually exclusive unless otherwise indicated herein. For example, a feature described or depicted in one embodiment may also be included in other embodiments, but is not necessarily included. Thus, the present invention encompasses a variety of combinations and/or integrations of the specific embodiments described herein.
As used herein, the phrase “and/or,” when used in a list of two or more items, means that any one of the listed items can be employed by itself or any combination of two or more of the listed items can be employed. For example, if a composition is described as containing or excluding components A, B, and/or C, the composition can contain or exclude A alone; B alone; C alone; A and B in combination; A and C in combination; B and C in combination; or A, B, and C in combination.
As used herein, “percent identity” between amino acid or nucleic acid sequences is synonymous with “percent homology,” which can be determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87 2264-2268 (1990)), modified by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90 5873-5877, (1993)). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., Basic Local Alignment Search Tool, J. Mol. Biol. 215 403-410, (1990). BLAST nucleotide searches are performed with the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches are performed with the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences homologous to a reference polypeptide (e.g., SEQ ID NO. 1). To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described in Altschul et al., Gapped BLAST and PSI-BLAST: A new generation of protein database search programs, Nucleic Acids Res. 25 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used which are available from the National Institutes of Health. A variant can also include, e.g., an internal deletion or insertion, a conservative or non-conservative substitution, or a combination of these variations from the sequence presented. In any event, it will be appreciated that fragments of the sequences described herein must remain “functional” as compared to the original sequence. Thus, the term “functional fragment” refers to sequences that may include insertion, deletions, and the like, but which nonetheless comprise or encode for a protein that retains the functionality of the original sequence (e.g., original binding specificity or ability, etc.).
The present description also uses numerical ranges to quantify certain parameters relating to various embodiments of the invention. It should be understood that when numerical ranges are provided, such ranges are to be construed as providing literal support for claim limitations that only recite the lower value of the range as well as claim limitations that only recite the upper value of the range. For example, a disclosed numerical range of about 10 to about 100 provides literal support for a claim reciting “greater than about 10” (with no upper bounds) and a claim reciting “less than about 100” (with no lower bounds).
The following examples set forth methods in accordance with the invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.
In this study, we have labeled PA with 5-fluorotryptophan (5-FTrp) and have studied the impact of labeling on structure and stability, using tryptophan fluorescence, circular dichroism, X-ray crystallography, and 19F nuclear magnetic resonance (NMR). We also determined the effect of receptor binding on the stability to pH and temperature using 19F NMR. There are seven tryptophans located in two of the four domains of PA: domain 1 (residues 1-258), which includes the 20 kDa PA20 domain formed after cleavage by furin C-terminal to Arg167 and includes Trp65, −90, −136, −206, and −226; and domain 2 (residues 259-487), which includes Trp346 and Trp477. Trp346 is part of the domain 2β3-2β4 loop and is closest to the CMG2 binding interface.
19F NMR is a powerful tool for studying the structure and function of proteins, as it provides residue-specific information about environmental perturbations around each fluorine nucleus. On the basis of our 19F NMR studies, we show that the Trp346 resonance undergoes conformational exchange at low pH, with very little change in the other 19F resonances, providing further support that the domain 2β3-2β4 loop is particularly sensitive to pH. In addition, we show that receptor binding stabilizes the Trp346 resonance to variations in pH and temperature along with other tryptophan residues that are more distant from the binding interface. Finally, we have determined the structure of 5-FTrp-labeled PA to 1.7 A resolution, which exhibits nearly identical structural properties as the WT protein. Our studies highlight the use of 19F NMR to follow structural changes at a residue-specific level in a relatively high molecular weight protein and the positive impact of receptor binding on global protein stabilization.
Urea (electrophoresis grade) and 5-fluorotryptophan were obtained from Sigma (St. Louis, Mo.). The urea concentration was determined by the refractive index at room temperature, and the urea was stored at −80° C. until the day of the experiment. All other chemicals prepared were reagent grade. Escherichia coli strain DL41 was obtained as a gift from the Yale E. coli genetic stock center.
Plasmid pQE80-PA83 was used for generating mutations within the PA sequence. We used the following forward primers (SigmaGenosys, purified via high-performance liquid chromatography) to create the mutants and the corresponding reverse strands using the Quickchange mutagenesis kit from Stratagene:
Sequences were confirmed at the Protein Nucleic Acid Laboratory (PNACL) at Washington University in St. Louis (St. Louis, Mo.).
The pQE80-PA83 plasmid was transformed into E. coli tryptophan auxotrophic strain DL41 grown in the presence of 100 μg/mL ampicillin. Cells were grown in a defined medium that is identical to ECPM1, but substituting the casamino acids for defined amino acids. The tryptophan concentration was 0.25 mM. Cells were grown to an optical density (0D600) of 3.0 at 32° C. The cells then were washed twice with 0.9% NaCl; then the same medium containing 0.25 mM 5-FTrp in place of tryptophan was added to the cells, and the cells were resuspended. The cells were then incubated for 10 min prior to the addition of IPTG to a final concentration of 1 mM at 26° C., and grown for an additional 2-3 hours prior to harvesting.
For the preparation of PA, after the OD had reached 6.0, bacterial cells were centrifuged and resuspended in a buffer containing 20 mM Tris-HCl (pH 8.0), 20% sucrose, and 1 mM EDTA for 15 min at room temperature. The cells were centrifuged for 15 min at 8000 g and 4° C., and the pellet was resuspended in ice-cold 5 mM MgSO4. Before centrifugation, 1 M Tris-HCl (pH 8.0) was added to a final concentration of 20 mM, and cells were again centrifuged at 4° C. (8000 g). The supernatant was filtered (0.2 μM, Millipore) and applied to a Hi-Trap Q anion exchange column pre-equilibrated in 20 mM Tris-HCl (pH 8.0) at 4° C. PA was eluted with a NaCl gradient on an Akta Prime LC system. Fractions were concentrated using an Amicon Ultra-15 10 kDa centrifugal filter (Millipore) and then applied to a Sephadex S-200 gel filtration column pre-equilibrated in 20 mM Tris-HCl and 150 mM NaCl (pH 8.0) at 4° C. Pure protein fractions were identified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), pooled, and concentrated. CMG2 was prepared and purified as described previously (Rajapaksha et al. Monitoring anthrax toxin receptor dissociation from the protective antigen by NMR, Prot. Sci. 18, 17-23 (2009)). Briefly, a human cDNA corresponding to full-length CMG2 from Origene Technologies (Rockville, Md.) was used to clone the VWA domain of CMG2 (residues 38-218) into the expression plasmid pGEX-4T1, using BamH1-Not1 restriction sites as described previously (Wigelsworth et al. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J. Biol. Chem. 28; 279(22); 23349-56 (2004), incorporated by reference herein). pGEX-4T1 places a thrombin cleavable site glutathione s-transferase in the amino terminus of the expressed protein. The full length sequence of GST-CMG2 is in SEQ ID NO:5, where residues 225-406 are CMG2. A GST column using thrombin for elution of protein by cleaving the CMG2 and glutathione tag was used for protein purification.
Purification of PA20 was conducted using a trypsin nicking protocol, whereby 10 mg of PA or 5-FTrpPA was digested with 10 μg of Trypzean (Sigma) for 30 min at room temperature, followed by the addition of an excess of soybean trypsin inhibitor (100 μg) on ice. The PA20 was purified over a H-Trap Q column equilibrated in 20 mM Tris (pH 8.5) and 1 mM CaCl2, eluting with a NaCl gradient.
Data were recorded on a Cary Eclipse spectrofluorimeter equipped with a Peltier cooling system, using an excitation wavelength of 280 or 295 nm with slit widths set at 5 nm for both excitation and emission. All measurements were taken at 20° C. in a 50 mM Tris/25 mM MES/25 mM acetic acid buffer system, using 1 μM for pH experiments and 0.8 μM for the urea denaturation experiments. For the pH and urea experiments, only 295 nm excitation was used, recording emission data for the WT at 330 or 333 nm for the 5-FTrp-labeled PA or PA20 proteins, and the data are an average of five scans from 300 to 600 nm. All samples were incubated overnight at the respective pH or urea concentrations to allow for adequate equilibration. For the pH experiments, the solid lines through the data points are nonlinear least-squares fits of the data to the Henderson-Hasselbalch equation to give an apparent pKa for the pH transition. For the urea denaturation experiments, in the case of the full-length PA proteins, the data were fit to a three-state transition as described previously. For the PA20 urea denaturation experiments, the denaturation curves were fit to a two-state model with sloping baselines according to the model described by Clarke and Fersht. The curves were fit using Kaleidagraph version 3.6 (Synergy Software, Reading, Pa.).
Circular Dichroism (Far UV) Measurements were performed using a Jasco J810 spectropolarimeter. Spectra were measured in 10 mM HEPES (pH 8.0) at a concentration of 8 μM, using a 0.1 cm path length cell. The response time was 2 s, and the scan rate was 20 nm/min.
Spectra were acquired on a Varian INOVA 400 MHz spectrometer equipped with a tunable inverse detection probe. Spectra were recorded at 20° C. unless otherwise indicated, and sample concentrations were typically in the 200 μM range in 50 Tris/25 mM Mes/25 mM AcOH buffer (pH 8.0) with 10% D2O added for a field frequency lock. Spectra were acquired using a 90° pulse width and a recycle delay of 5 s and were referenced to an internal standard of 4-fluorophenylalanine as described previously. Spectra typically required >10000 transients for adequate peak visualization and were processed with 10 Hz of line broadening.
The 5-FTrpPA Glu712Cys protein was expressed and purified. We added 1 mM DTT to the final MgSO4/Tris (pH 8.0) step in the isolation of periplasm, and column buffers for purification included 1 mM DTT. The 5-FTrpPA was purified and the DTT removed by loading the protein solution onto a PD-10 column equilibrated with buffer containing 20 mM HEPES (pH 7.25) and 150 mM NaCl and then eluted using the same buffer. Immediately after purification, a 10-fold molar excess of MTSL [S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate] in methanol was added for 30 min at room temperature; then an additional 10-fold molar excess of MTSL was added, and this solution was incubated overnight at 4° C. The next day, MTSL was removed using an S-200 gel filtration column equilibrated in 50 mM Tris/25 mM Mes/25 mM AcOH buffer (pH 8.0) at 4° C. The sample was split into two aliquots, each containing 207 μL of PA, 50 μL of D2O, 1 μL of 10 mM p-fluorophenylalanine, and 217 μL of 50 mM Tris/25 mM Mes/25 mM acetic acid buffer. To one tube was added 25 μL of water, and to the other was added 25 μL of 100 mM TCEP. The final PA concentration in each tube was 150 μM.
5-FTrpPA was concentrated to 10 mg/mL in 150 mM NaCl and 10 mM Tris (pH 8.0) for crystallization. Screeing was conducted in Compact Jr. (Emerald biosystems) sitting drop vapor diffusion plates at 20° C. using equal volumes of protein and crystallization solution. Plate-shaped crystals (˜200 μm×100 μm) were obtained in 1 day from the Index HT screen (Hampton Research) condition E8 [35% (v/v) pentaerythritol propoxylate (5/4 PO/OH), 0.05 M HEPES (pH 7.5), and 0.2 M potassium chloride] equilibrated against 100 μL of the crystallization solution at 20° C. Single crystals were transferred to a fresh drop of the crystallization solution (Index E8), which served as the cryoprotectant, and frozen in liquid nitrogen prior to the collection of data. Initial X-ray diffraction data were collected in house using a Bruker Microstar microfocus rotating anode generator equipped with Helios MX multilayer optics and a Platinum-135 CCD detector. Data were processed using the Proteum2 software package (Bruker-AXS). High-resolution data were collected at the Advanced Photon Source IMCA-CAT beamline 17ID using a Dectris Pilatus 6M pixel array detector.
Intensities were integrated using XDS, and Laue class analysis and data scaling were performed with Aimless, which suggested that the highest-probability Laue class was mmm and space group P212121. The structure was determined by molecular replacement with Molrep using a previously determined structure of the protective antigen as the search model [Protein Data Bank (PDB) entry 3MHZ)] as the search model. The in-house X-ray diffraction data, processed to 2.2 Å resolution, were used for the initial structure solution and refinement, and the higher-resolution synchrotron data were used for refinement of the final model. Structure refinement using and manual model building were conducted with Phenix and Coot, respectively. TLS refinement was incorporated in the final stages to model anisotropic motion. Structure validation was conducted with Molprobity, and figures were prepared using the CCP4MG package. Coordinates and structure factors for 5-FTrpPA were deposited to the Protein Databank with the accession code 4NAM.
PA was labeled with commercially available 5-FTrp using the tryptophan auxotroph DL41, and proteins were >95% labeled as determined by electrospray mass spectrometry (ESI-MS). To determine the effect of labeling on the structure and stability of PA, we compared labeled and unlabeled proteins by far-UV circular dichroism (CD) to compare secondary structural content and measured the stability of the proteins to urea and pH using fluorescence. The fluorescence emission spectrum (excitation at 280 or 295 nm) of WT PA and 5-FTrpPA at 1 μM in 50 mM Tris/25 mM Mes/25 mM AcOH buffer (pH 8.0) at 20° C. is shown in
The unfolding of 5-FTrpPA as a function of pH is similar to that of the WT protein, with a pKapp of 5.3 compared to a pKapp of 5.8 for the WT protein. In contrast to pH unfolding, which exhibits a single transition, the unfolding of PA and 5-FTrpPA by urea at 20° C. and pH 8.0 exhibits two transitions, one with a midpoint (CM) at ˜1 M urea and a second that occurs at a CM of ˜4 M urea. The results from the pH and urea studies are summarized in Table 1.
aAll data were recorded at 20° C. using a Cary Eclipse spectrofluorimeter.
bErrors in pKapp were determined by best fit to the Henderson-Hasselbalch equation, and errors in m and CM were obtained from nonlinear least-squares fitting of the data to a three-state model in Kaleidagraph.
cErrors in ΔG° were determined using the relationship [m2(seCM2) ± CM2(sem2)]1/2, where seCM2 and sem2 are the standard errors in CM and m, respectively.
dPA20 ΔG° values were determined for a single two-state N ↔ U transition with sloping baselines.
The isolated PA20 (residues 1-167) domain exhibits an unfolding transition that matches the second transition observed in the fluorescence unfolding of PA (inset of
On the basis of these observations, we assigned the resonances that disappear at ˜2 M urea to that of the PA63 region and the remaining folded resonances that persist up to 4 M urea to the PA20 domain. To confirm this assignment, we conducted limited proteolysis of the labeled PA with trypsin, which can be used in lieu of furin to cleave PA20 from PA83, isolated PA20, and compared the resonances at 0 and 3.2 M urea to that of the WT protein (
At this point, we decided not to pursue assignment of the PA20 resonances by mutagenesis but rather focus on those resonances that would be found in the heptameric prepore state. To assign the resonances in the PA63 region, we introduced relatively conserved mutations (Trp→Phe or Tyr) that in theory would not disrupt stability or folding and thus not perturb the 19F NMR spectrum; the mutation would result only in a loss of one of the resonance peaks. The following mutants were made: Trp206Tyr, Trp226Phe, Trp346Tyr, and Trp477Phe. We could not produce the labeled Trp226Phe and Trp477Phe proteins, probably because of an effect on the stability of the protein. Trp226 is relatively solvent exposed but is located ˜5 Å from the two calcium ions in the structure, and the carbonyl of Trp226 forms a hydrogen bond with the amide hydrogen of Asp235, which coordinates one of the calcium ions. Thus, a tryptophan at position 226 may provide a necessary conformational constraint for calcium binding that cannot be achieved if this residue is a phenylalanine. Trp477 is near the N-terminus of the domain 2α3 helix that bridges interactions with domain 3, and local contacts around Trp477 include Pro232 and Tyr233 (domain 1′) and Pro260, Pro373, and Ileu459 (domain 2), forming a hydrophobic pocket. A phenylalanine at this position may disrupt the local van der Waals contacts, potentially destabilizing contacts that span a range of ˜200 residues.
We could produce the labeled Trp346Tyr, but only at very low levels. In initial experiments, we tried labeling the Trp346Phe mutant for which we have a three-dimensional crystal structure; however, this labeled protein proved to be too unstable, and we could not accumulate enough pure protein for a spectrum. We were able to obtain enough labeled protein for a spectrum of Trp346Tyr (
The Trp206Tyr protein exhibits a spectrum that is nearly identical to that of the WT labeled protein, and the only loss in intensity that we observe is the loss of the small peak at −47.2 ppm (
To determine whether the line broadening of Trp206 was due to factors that depended on the protein conformation, we purified both the labeled PA and Trp206Tyr proteins and partially denatured these at 3.2 M urea, which is at the midpoint between the two identified transitions. The addition of denaturant to the approximate midpoint of the transition should lead to unfolded resonances corresponding to Trp206, -226, -346, and -477, while the resonances corresponding to PA20 should remain largely folded. For Trp206Tyr, the unfolded resonance should exhibit a smaller amplitude, corresponding to the loss of a single fluorine. At 3.2 M urea, we observe a major resonance at −47.2 ppm, and three smaller resonances (−43.6, −46, and −47 ppm) (
To further determine if there are structural changes upon labeling, we crystallized the W206Y mutant, the structure of which was determined to 1.7 Å resolution. The structure is shown in
I/σ(I)
a
aValues in parentheses are for the highest-resolution shell.
bRmerge = ΣhklΣi|Ii(hkl) − I(hkl)
|/ΣhklΣiIi(hkl), where Ii(hkl) is the intensity measured for the ith reflection and
I(hkl)
is the average intensity of all reflections with indices hkl.
cRfactor = Σhkl||Fobs(hkl)| − |Fcalc(hkl)||/Σhkl|Fobs(hkl)|; Rfree is calculated in an identical manner using 5% of the randomly selected reflections that were not included in the refinement.
dRmeas equals the redundancy-independent (multiplicity-weighted) Rmerge. Rpim equals the precision-indicating (multiplicity-weighted) Rmerge.
eCC1/2 is the correlation coefficient of the mean intensities between two random half-sets of data
For example, when comparing the structure of 5-FTrp to those of the WT (PDB entry 3Q8B) and 2-fluorohistidine-labeled (PDB entry 3MHZ) forms, we noticed that particular regions could be traced to the electron density maps in the former that were disordered in the latter two structures. This includes the Lys72-Lys73 backbone, Glu51-Glu54, and the Ser168-Val175 loop. The Ser168-Val175 loop is in the proximity (3.5-4.0 Å) of Trp90 (
Because of the instability of the Trp346Tyr mutant, we could not conclusively assign this resonance (
We wanted to further explore the effect of receptor binding on the structure of the protein, focusing on the temperature dependence of the resonances. Our expectation was that the Trp346 resonance would experience an increase in the level of chemical exchange as the temperature increased, reducing the resonance amplitude. The results of our temperature experiments in the absence of receptor are shown in
In
PA undergoes several structural changes during the course of anthrax toxin pathogenesis, including receptor binding followed by oligomerization and endocytosis, and at acidic pH the formation of a membrane-spanning pore. In an effort to improve our understanding of these structural changes at a residue-specific level, we have conducted an initial study whereby we have biosynthetically incorporated 5-FTrp into the monomeric, 83 kDa form of PA and have used 19F NMR to probe the structure of the protein under a variety of conditions.
To determine the effect of fluorine labeling on the stability of the protein, we conducted pH and urea denaturation experiments, following unfolding by monitoring the changes in tryptophan fluorescence. The results of these experiments, which again are summarized in Table 1, suggest that while 5-FTrpPA is slightly more stable to acidic pH than the WT, the 5-FTrp-labeled PA or PA20 domain exhibits a small decrease in the ΔG° of unfolding to urea, which seems mainly attributable to differences in the m values. However, an important caveat in the interpretation of these differences is the fact that the fluorescence properties of the 5-FTrp and Trp are different (see
We also report the 1.7 Å crystal structure of the 5-FTrp-labeled PA Trp206Tyr, and the structure shows some small differences in comparison to that of the WT protein, most notably the fact that we are able to observe regions of electron density that are missing in the WT structure. Importantly, both structures overlay well with one another (
The ability to assign the Trp346 resonance, which lies near the interface between PA and CMG2, allowed us to probe how this resonance changes in the presence of the receptor and whether the Trp346 resonance is sensitive to variations in pH. The first crystal structure of PA postulated that the domain 2β3-2β4 loop was sensitive to pH and that at lower pH values the electron density within this region became disordered. We have also crystallized PA and compared structures a low and high pH; in some structures, we could observe an increase in the level of disorder at low pH (˜5), whereas the WT protein, surprisingly, showed no increase in the level of disorder. We find that the resonance intensity of Trp346 specifically decreases as the pH is lowered, providing strong evidence that the domain 2β3-2β4 loop undergoes conformational exchange at low pH. The mechanism of the structural change that occurs in this loop as the pH is lowered has yet to be determined.
Receptor binding clearly has a stabilizing influence on the structure of the protein. While Trp346 undergoes a substantial chemical shift change (˜0.6 ppm) upon receptor binding, we did not observe the same loss of intensity of this resonance either at low pH or at higher temperatures. Also, the unfolded resonance intensity is attenuated (low pH or higher temperatures) when the receptor is bound. The effects that we observe on the temperature dependence of the resonances suggest that the receptor stabilization is not only local to the binding interface but also more long-range. This effect is consistent with studies following histidine hydrogen-deuterium exchange kinetics, in which the rates of histidine hydrogen-deuterium exchange were slowed upon receptor binding, even for residues >40 Å from the binding interface.
The studies presented here provide an initial step toward following the conformational changes that occur in the anthrax toxin at low pH. On the basis of the experiments reported here, the feasibility of using 19F NMR to follow structural changes in PA is warranted. One important question we wish to address using this method is the order of events leading to the formation of a pore. It has been proposed that an initial step in the formation of the pore from the prepore state is the closure of the φ-clamp, a ring of phenylalanines (Phe427) located within the lumen of the pore that clamps down on its substrate (either edema factor or lethal factor) and is required for protein translocation. In initial experiments, we have used mutagenesis to replace this phenylalanine with a tryptophan and have labeled the protein with 5-FTrp, and we are able to observe this resonance (F-Trp427) in the prepore and pore states. Therefore, in the future, we should be able to follow this resonance during the process of pore formation in real time. In any case, 19F NMR opens the possibility of exploring structural changes in this protein at a residue-specific level.
PA binding to the host cell receptor capillary morphogenesis protein-2 (CMG2), either to the monomeric 83 kDa PA4 or the heptameric prepore. Both structural and biochemical studies of the PA-CMG2 complex indicate that the binding interface is comprised of domain 4 and a small loop from domain 2 (2β3-2β4 loop), which inserts into a groove on the surface of CMG2 (
To further investigate the changes in stability of PA upon CMG2 binding, we used a histidine hydrogen-deuterium exchange (His-HDX) method, which monitors the slow rate of HDX of the C2 hydrogen of the imidazole group of histidine, and followed the rate of HDX as a function of increasing concentrations of guanidinium hydrochloride (Gdn-HCl). Thus, using this method, we can measure the equilibrium unfolding of specific histidine residues within the protein. There are 10 histidine residues in PA that are scattered throughout the molecule, one in the PA20 domain, two in domain 1′, five in domain 2, and two in domain 4. Herein, we show that receptor binding leads to a significant shift in the concentration of Gdn-HCl required for full HDX (unfolding) of histidines located in separate domains, suggesting that receptor binding has a global effect on the thermodynamic stability of the protein. These studies are corroborated using fluorescence, in which we were able to probe selectively fluorescence changes in PA using a 4-fluorotryptophan-labeled von Willebrand factor A (vWA) domain of CMG2, which is nonfluorescent. His-HDX-MS also allowed us to determine the pKa and more accurate solvent accessibilities of the histidines in the presence and absence of the receptor and reveal differences in the microenvironment around the histidine residues as a consequence of receptor binding. Our results indicate that receptor binding has a profound long-range impact on the stability and structure of PA, suggesting that, with a limit on hingelike motions between domain 2 and domain 4, the protein can be made to be significantly more stable. Because PA is the major antigenic component of the current anthrax vaccine, our studies would indicate that addition of CMG2 to a vaccine formulation could improve the stability and overall efficacy of the vaccine.
Materials and Methods
Deuterium oxide (D2O, 99%) was purchased from Cambridge Isotope laboratories (Andover, Mass.), and guanidine hydrochloride (Gdn-HCl), deuterium chloride (DCl), and sodium deuteroxide (NaOD) were from Sigma-Aldrich (St. Louis, Mo.). Lys-C was purchased from Wako Chemicals USA (Richmond, Va.); chymotrypsin and thermolysin were from Sigma-Aldrich, and Glu-C was from Worthington Biochemical (Lakewood, N.J.). All other chemicals and materials used were either reagent grade or of the highest quality commercially available.
PA and the vWA domain of CMG2, encoding residues 38-218, were expressed and purified as described previously.(14-16) Labeling of CMG2 with 4-fluorotryptophan was conducted using the tryptophan auxotroph DL41 (provided as a gift from the Yale E. coli Genetic Stock Center). 4-Fluorotryptophan was purchased from Gold Biotechnology (St. Louis, Mo.).
PA alone (0.5 nmol) and the PA-CMG2 complex (0.5 nmol of PA and 2.5 nmol of CMG2) were incubated in 100 μL of 100 mM HEPES (pH* 7.5) made with D2O containing 1 mM MgCl2 and various concentrations of Gdn-HCl for 48 h at 37° C. The pH* of the buffer was adjusted with diluted NaOD with a Solution Analyzer model 4603 instrument (Amber Science, Eugene, Oreg.) equipped with a glass AgCl electrode (model 476086, Nova Analytics, Woburn, Mass.). The reported pH* values are direct pH meter readings of the D2O buffer solutions calibrated with standard buffer solutions made with H2O and are uncorrected for the isotope effect at the glass electrode. The reaction was stopped by adding 10 μL of formic acid, and the protein was freed from the salts using an Ultra Micro Spin C4 column (Nest Group, Southboro, Mass.) following the manufacturer's instructions and dried in a Speed Vac.
The protein was then redissolved in 60 μL of 100 mM ammonium bicarbonate and digested by 2 μg of Lys-C for 30 min at 25° C. The reaction was stopped by adding 10 μL of formic acid, and the digest was divided into three parts and then dried in a Speed Vac. Two parts were further digested, one part by 1 μg of Glu-C for 30 min and other part by 1 μg of chymotrypsin for 30 min. The resulting three digests were dried in a Speed Vac and redissolved in 30 μL of 0.1% trifluoroacetic acid (TFA). The three digests at particular Gdn-HCl concentrations were mixed and analyzed by liquid chromatography and tandem mass spectrometry (LC-MS/MS) using a Qstar quadrupole/time-of-flight mass spectrometer (Applied Biosystems-MDS Sciex, Foster City, Calif.) equipped with a TurbolonSpray ion source. The protein digests were injected into a reverse-phase C18 column (500 mm×0.1 mm, Waters); the peptides were chromatographed using a linear gradient of acetonitrile from 2 to 50% in aqueous 0.1% formic acid over a period of 40 min at a rate of 30 μL/min, and the elute was directly introduced into the mass spectrometer. The total ion current was obtained in the mass range of m/z 400-2000 in the positive ion mode with an acquisition time of 1 s for each scan.
The pseudo-first-order rate constant (k) of the HDX reaction was determined by monitoring changes in the ratios of the M+1/M isotopic peak of a given peptide before (time zero) and after (time t) the HDX reaction, and fitting the data to a first-order rate equation,(17) and the values were corrected upward to offset the decreased solvent concentration caused by the volume effect of Gdn-HCl. The relationship between solvent concentration and Gdn-HCl concentration was experimentally determined, from which the correction factor to correct the rate constant of the HDX reaction in Gdn-HCl solutions was obtained. The corrected HDX rate was plotted against the concentration of Gdn-HCl. From the plot, the midpoint (Cm) of the Gdn-HCl-induced unfolding transition was estimated by fitting the denaturation curve to a two-state model. The free energy change (ΔG°) in PA denaturation was estimated from the plot by calculating the equilibrium constant (Keq) of denature/native protein at each Gdn-HCl concentration as follows.
where k is the first-order His-HDX rate constant at a specific Gdn-HCl concentration, kN is the k for the native protein (k at 0 M Gdn-HCl), and kD is the k for the fully denatured protein (can be obtained from the plateau of the sigmoidal curve). The Keq value was used to determine the free energy change of denaturation at each Gdn-HCl concentration with the equation
ΔG°=−RT ln Keq
where R is the gas constant and T is the absolute temperature in kelvin. By plotting the ΔG° values against the concentrations of Gdn-HCl and extrapolating the fitted line to 0 M Gdn-HCl, we obtained ΔG° water in the absence of Gdn-HCl.
PA alone and PA (1 μmol) complexed with 4-fluorotryptophan-labeled CMG2 (4-FTrpCMG2, 2 μmol) in 100 mM HEPES (pH 7.5) containing 1 mM MgCl2 and various concentrations of Gdn-HCl were placed in a Cary-Eclipse fluorimeter, and the fluorescence emission spectra were recorded at 20° C. by exciting the tryptophan residues in PA at 295 nm and monitoring the emitted light at 334 nm. The data were fit to a three-state transition in the absence of CMG2 as described by Wimalasena, D. S. et al. ((2007) Effect of 2-fluorohistidine labeling of the anthrax protective antigen on stability, pore formation, and translocation. Biochemistry 46, 14928-14936.)
The method described by Young and co-workers was used to conduct the pulse proteolysis experiment. (Young, T. A. et al. (2007) Comparison of proteolytic susceptibility in phosphoglycerate kinases from yeast and E. coli: Modulation of conformational ensembles without altering structure or stability. J. Mol. Biol. 368, 1438-1447.)
PA (100 μg, 6 μM) or PA with 48 μg (12 μM) of CMG2 was incubated overnight at room temperature in 200 μL of 20 mM Tris buffer (pH 8.0) containing 150 mM NaCl, 10 mM CaCl2, and 1 mM MgCl2. The next day, 20 μL of 5 mg/mL thermolysin prepared in 2.5 M NaCl and 10 mM CaCl2 was added to the 200 μL of PA and PA-CMG2 complex samples and incubated at room temperature for various periods of up to 120 min. Aliquots (15 μL) were withdrawn at the different time points, to which 5 μL of 50 mM EDTA and 4 μL of 6× SDS-PAGE sample buffer were added to stop the proteolysis. The solution was then boiled for 5 min, and 15 μL of the solution was run on a 15% SDS-PAGE gel.
PA (0.5 nmol) and the PA-CMG2 complex (0.5 nmol of PA and 2.5 nmol of CMG2) were placed in 100 μL of buffer with different pH* values (4.5-9.0) that contains 20 mM CHES, 20 mM HEPES, 20 mM MES, 50 mM NaCl, and 1 mM MgCl2 and incubated for 50 h at 37° C. The pH* of the buffer was adjusted with diluted DCl or NaOD. The reaction was stopped by adding 5 μL of formic acid, and the protein was freed from the buffer salts using an Ultra Micro Spin C4 column (Nest Group) according to the manufacturer's instructions and dried in a Speed Vac. The protein was redissolved in 100 mM ammonium bicarbonate and digested with Lys-C alone, a combination of Lys-C and Glu-C, or a combination of Lys-C and chymotrypsin as described above. The resulting digests were dried in a Speed Vac, redissolved in 0.1% TFA, and then analyzed by LC-MS/MS using an LTQ-Orbitrap XL mass spectrometer. The pseudo-first-order rate constant (k) of the HDX reaction was determined as described above, and the k values were plotted as a function of pH*, from which the pKa of each histidine residue and the half-life (t1/2) of the HDX reaction were determined.
A comparison of protein structures was performed using PyMOL (Molecular Graphics System software, DeLano Scientific, Palo Alto, Calif.). The structural data of PA (PDB entry 3Q8B) and the PA-CMG2 complex (PDB entry 1T6B) deposited in the Protein Data Bank were used in the comparison. The same structural data were used to obtain the ASA (solvent accessible surface are) values for the C2 atoms of the histidine residues using GETAREA.
To investigate how the stability of PA changes upon binding to CMG2, we conducted Gdn-HCl-induced equilibrium unfolding experiments on PA alone and PA complexed with CMG2, using His-HDX-MS. Histidine residues in a protein that are protected (to at least a certain extent) from the solvent become exposed to solvent upon unfolding of the protein caused by increasing concentrations of Gdn-HCl, which subsequently increases the magnitude of HDX rates for the histidine residues as the protein unfolds. The histidine residues we monitored were His211, His253 (domain 1′), His336 (domain 2), and His616 (domain 4). Four peptides containing these four histidine residues, each containing one histidine residue, were detected by LC-MS/MS, and their precursor ion spectra were used to calculate the pseudo-first-order rate constants (k) for their HDX reactions.
During the study, it became apparent that the HDX rates obtained in the Gdn-HCl solution must be corrected upward. This is because the concentration of water in a highly concentrated Gdn-HCl solution (e.g., 5 M Gdn-HCl) is significantly lower than the concentration of water in a solution without Gdn-HCl. This means that the amount of a heavy water molecule (D2O) available in such a solution in a defined volume is significantly small, causing us to underestimate the HDX rates. We determined the relationship between the water and Gdn-HCl concentrations in various concentrations of Gdn-HCl solutions, from which an equation to correct upward the experimentally obtained HDX rates was obtained (see the Supporting Information). All the HDX rates measured in Gdn-HCl solutions were corrected using this equation.
In
aThe standard errors are associated with the sigmoidal curve fitting.
The Cm value at His336 could not be determined, because this histidine is already exposed well to solvent in the native structure as indicated by the high HDX rate for this residue at 0 M Gdn-HCl (
Previous fluorescence and 19F NMR unfolding experiments in urea have shown that PA unfolds in two transitions, the first transition being assigned to the unfolding of domains 1′-4 and the second transition being mainly due to the PA20 domain, which after cleavage with furin can freely dissociate and is stable on its own. Here, we followed the Gdn-HCl-induced unfolding of PA by fluorescence in the presence of CMG2, where we have labeled CMG2 with 4-fluorotryptophan (4-FTrp). This effectively eliminates the fluorescence contribution from the sole tryptophan (Trp59) of CMG2, because 4-FTrp is a nonfluorescent analogue of tryptophan (see the inset of
Resistance to proteolysis is an effective way to probe accessibility to unfolded conformations in a protein, and we hypothesized that CMG2 binding would “tighten” the structure of the protein and decrease the rate of proteolytic degradation. To test whether binding of CMG2 stabilizes PA against proteolysis, we incubated PA and the PA-CMG2 complex (1:2 ratio) at room temperature with 100 μg thermolysin for different periods of time (up to 120 min) and analyzed the resulting reactions by SDS-PAGE. Aliquots were withdrawn at the different time points and run on a 15% SDS-PAGE gel. In the case of PA alone, the undigested PA band disappeared within 30 s and appeared to be cleaved into two fragments (50 and 40 kDa) (
In previous studies, we compared, using His-HDX-MS, the effect of CMG2 binding on the rate of exchange at pH* 9.5; however, we were unable to determine the pKa values of the histidines, which this technique also allows. Therefore, in a manner similar to our previous work, we conducted a pH* titration study on PA alone and the PA-CMG2 complex using His-HDX-MS. The protein was deuterated in different pH* buffers (4.5-9.0), digested, and then analyzed by LC-MS/MS. All 10 histidine residues were detected in different peptides, described in the supplementary information from Mullangi et al. (2014) Long-Range Stabilization of Anthrax Protective Antigen upon Binding to CMG2, Biochemistry, 53 (38), pp 6084-6091, incorporated by reference herein in its entirety. The rate constants (k) for HDX of those histidine residues were calculated directly from their precursor ion spectra. The obtained k values as a function of pH* for six histidine residues (His86, His263, His304, His310, His336, and His597) are shown in
We believe this curve reflects the increased local conformational fluctuation and reversible unfolding around this residue at alkaline pH*, causing the histidine residue to be exposed more to solvent, rather than reflecting the acid dissociation of this residue. The phenomenon was not observed for the same residue in the PA-CMG2 complex (
Measured pKa values from the sigmoid curves for His86, His304, His310, His336, and His597 are shown in Table 4.
aThe standard errors are associated with the sigmoidal curve fitting.
bThe pKa could not be determined mainly because of the slow HDX rate.
cCalculated from k at pH 9.0 instead of using kmax, because kmax could not be obtained because of the lack of an interpretable sigmoidal curve.
Significant changes in pKa for His86 and His310 were observed, which was surprising given that His86 is >90 Å from the binding interface. In general, the pKa of histidines depends on several factors; however, the lower the pKa (<6), the stronger the tendency to be buried and uncharged at neutral pH, while a higher pKa (>7.5) generally reflects the greater potential for charge-charge interactions. The pKa of His86 decreased 0.61 pH unit upon binding to CMG2 (from ˜6.7 to 6.1), while the pKa of His310 increased 1.68 pH units. In previous work, we compared the distances of the histidine residues to potential hydrogen bond donors and/or acceptors and in general found that the distances became shorter in the presence of CMG2. Indeed, for His86, the distance to the Gln121 backbone carbonyl decreases from 3.43 to 3.07 Å, and this decreased distance is likely reflected in a slight lowering of the pKa. In contrast to that of His86, the pKa of His310 increased 1.68 pH units upon binding to CMG2, from 6.26 to 8.06. We are not able to offer an interpretation of the observed pKa change of this residue because His310 is not observed in the crystal structures of PA and the PA-CMG2 complex. However, the increased pKa suggests that one or more acidic side chains (e.g., Asp or Glu) may come close to His310 upon binding to CMG2. Indeed, Glu308, Glu302, and Asp315 are local candidates for interacting with His310.
In addition to His86 and His310, we were able to determine the pKa values of His263 (for only the PA-CMG2 complex), His304, His336 (for only PA), and His597. The pKa of His263 in the PA-CMG2 complex was determined to be 6.77, which is close to the intrinsic pKa value of a histidine residue (pKa≈6.5), suggesting little electrostatic influence of the neighboring groups on this residue. The pKa of His336 in PA was slightly higher (7.25) than the intrinsic pKa value of the histidine residue, suggesting there is a moderate influence of the electron-donating group(s) around this residue. The pKa values of His597 in both PA and the PA-CMG2 complex were shifted almost 2 pH units toward alkaline values (≥8), indicating there is a negatively charged group(s) in the proximity of this histidine. As expected, the imidazole ring of His597 is in the proximity of the carboxyl group of Asp608 and likely forms a salt bridge to this residue, in agreement with the crystal structure.
We previously reported the half-lives [t1/2 (days)] of the HDX reactions of histidine residues in PA. Those t1/2 values were calculated from the HDX rates obtained at a single pH* (9.5). In this study, we calculated the t1/2 values from the maximal rate constant (kmax) obtained from the plateau to the alkaline side of the sigmoid titration curve. The t1/2 values calculated in this way are considered to be more accurate, because they are calculated from the kmax values obtained from the pH* titration curves fit to multiple data points. The t1/2 values for His86, His263 (for only the PA-CMG2 complex), His304, His310, His336 (for only PA), and His597 were successfully determined from their kmax values and are listed in Table 4. We could not obtain interpretable sigmoidal curves for the remaining histidine residues mainly because of their slow HDX rates; therefore, the t1/2 values for those histidine residues were calculated from the k obtained at pH* 9.0.
The significant increases in t1/2 values due to receptor binding were observed for three histidine residues, His263, His304, and His336, suggesting that their solvent accessibilities decreased upon receptor binding. The increased t1/2 value for His263 is probably due to the increased level of stabilization of the local structure against alkaline pH* that occurs upon receptor binding as discussed above. Because His263 and His336 are observed in structures of PA and the PA-CMG2 complex, we compared the solvent accessible surface area (ASA) values for the C2 atoms of the histidine residues. The ASA values for His263 and His336 in both structures were comparable (His263, 15.5 Å2 for PA and 11.1 Å2 for the PA-CMG2 complex; His336, 20.3 Å2 for PA and 18.1 Å2 for the PA-CMG2 complex). Therefore, we cannot explain the results based on the ASA values. This discrepancy may reflect the difference in protein structures in the solution and crystals. The HDX reaction of the C2 hydrogen of the imidazole group occurs only when the neutral and protonated forms of the imidazole group are in equilibrium and the C2 atom is in direct contact with water. Therefore, the HDX reaction can be diminished when the number of water molecules assisting the acid-base equilibrium of the imidazole group or having contact with the C2 atom is reduced. Thus, our results indicate that receptor binding tightens the structure of PA, which leads to expelling water molecules around these histidine residues.
Our Gdn-HCl-induced unfolding experiments clearly show that PA is stabilized by CMG2, and the stabilization occurs not only in the domain that directly interacts with CMG2 (His616 located in domain 4) but also in domains that do not have direct contact with CMG2 (His211 and His253 located in domain 1′). Thus, we can safely say that both our combined His-HDX, fluorescence, and protease sensitivity assays indicate that the stabilization afforded by binding of CMG2 occurs up to His211 (which is ˜70 Å from the binding interface) does not seemingly further influence the stability of the PA20 domain. Nonetheless, our pH titration study using His-HDX-MS revealed that the microenvironment around histidine residues in PA20, domain 2, and domain 4 changes upon receptor binding. The altered pKa of His86 in the PA20 domain indicates that the binding to CMG2 influences the microenvironment of His86 even though the residue is far from the CMG2 binding interface (>90 Å).
How does receptor binding influence residues that are far from the binding interface? Previous experiments have indicated that domain 2 and domain 4 are part of a hinge that dictates the oligomeric assembly of PA63, such that a tighter interaction favors the formation of heptamers, whereas a weaker interaction may favor the formation of octamers. This implies that domain 2 and domain 4 are capable of hingelike dynamic motions that likely give rise to an overall plasticity in the protein. By anchoring the domain 2-domain 4 interface, hingelike motions are prevented, which in turn would effectively stabilize domain-domain interactions and other noncovalent interactions within the protein.
PA is the key component of anthrax vaccines currently licensed as well as vaccines under development. Efforts to develop protective adjuvants that do not require the use of a cold chain for storage in areas where a cold chain is not accessible or feasible are ongoing. Our study finds that CMG2 thermodynamically stabilizes PA, and thus, CMG2 may prevent structural perturbations to the protein under long-term storage conditions. Further, the addition of CMG2 slowed the rate of proteolysis by thermolysin. Addition of CMG2 to the vaccine formulation may prevent premature degradation of the protein post-injection, possibly allowing for a greater proportion of PA to ultimately be presented on antigen-presenting cells. Finally, depletion of the actual PA concentration amenable for interacting with the host immune system likely occurs because of the interaction of PA with receptors present on the surface of host cells, and the inclusion of CMG2 in a vaccine formulation should prevent such a depletion of PA.
Studies have shown that amide HDX in combination with mass spectrometry can be used to provide information about the stability of specific regions within a protein. This work demonstrates that His-HDX-MS is complementary to amide HDX, and to other conventional methods such as fluorescence spectroscopy and CD spectroscopy for monitoring protein stability. The advantages of this method over other methods include (1) the ability to follow the side chain stability at a single histidine, which may be more sensitive to the folded state of a protein (because it may be the last part to be stabilized), and to monitor the stabilities of different sites within a protein simultaneously, (2) compared to NMR or CD, the absence of a requirement for large amounts of protein, (3) the fact that proteins do not have to be pure, because mass spectrometry can detect peptide masses even in complex mixtures, and (4) the fact that proteins can be in seemingly any environment, such as a soluble monomer or part of a large oligomeric multiprotein complex within the membrane. These advantages will allow us to study the stabilities of proteins in more complex structures and cellular milieu.
The present application is a divisional of U.S. Ser. No. 14/987,505, filed Jan. 4, 2016, which claims the priority benefit of U.S. Provisional Patent Application Ser. No. 62/099,356, filed Jan. 2, 2015, entitled PROTECTIVE ANTIGEN COMPLEXES WITH INCREASED STABILITY AND USES THEREOF, each of which is incorporated by reference in its entirety herein.
The present invention was supported in part by the National Institutes of Health (“NIH”) grant R21-EY021595, and NIH-KINBRE award under INBRE Grant P20GM10341, and the federal government may have certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62099356 | Jan 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14987505 | Jan 2016 | US |
| Child | 15886112 | US |
